BerGenBio ASA (BGBIO.OL)
NOK 8.72
(-2.83%)
NOK 8.72
(-2.83%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -155.55 Million NOK | -3.84% |
| 2022 | -149.79 Million NOK | 65.51% |
| 2021 | -434.26 Million NOK | 39.57% |
| 2020 | -718.6 Million NOK | -185.0% |
| 2019 | -252.14 Million NOK | 29.89% |
| 2018 | -359.61 Million NOK | -2.96% |
| 2017 | -349.29 Million NOK | -143.95% |
| 2016 | -143.18 Million NOK | -98.11% |
| 2015 | -72.27 Million NOK | 42.8% |
| 2014 | -126.35 Million NOK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -117.34 Million NOK | 24.56% |
| 2024 Q2 | -200.11 Million NOK | -70.53% |
| 2023 FY | -155.55 Million NOK | -3.84% |
| 2023 Q3 | -169.21 Million NOK | 25.12% |
| 2023 Q1 | -72.34 Million NOK | 51.7% |
| 2023 Q4 | -155.55 Million NOK | 8.07% |
| 2023 Q2 | -225.98 Million NOK | -212.37% |
| 2022 Q4 | -149.79 Million NOK | 33.45% |
| 2022 FY | -149.79 Million NOK | 65.51% |
| 2022 Q1 | -367.03 Million NOK | 15.48% |
| 2022 Q2 | -291.49 Million NOK | 20.58% |
| 2022 Q3 | -225.07 Million NOK | 22.79% |
| 2021 FY | -434.26 Million NOK | 39.57% |
| 2021 Q4 | -434.26 Million NOK | 14.58% |
| 2021 Q3 | -508.39 Million NOK | 11.24% |
| 2021 Q2 | -572.79 Million NOK | 12.96% |
| 2021 Q1 | -658.07 Million NOK | 8.42% |
| 2020 Q2 | -828.38 Million NOK | -97.52% |
| 2020 Q1 | -419.39 Million NOK | -66.33% |
| 2020 FY | -718.6 Million NOK | -185.0% |
| 2020 Q4 | -718.6 Million NOK | 7.62% |
| 2020 Q3 | -777.85 Million NOK | 6.1% |
| 2019 Q2 | -324.13 Million NOK | -5.78% |
| 2019 Q1 | -306.41 Million NOK | 14.79% |
| 2019 FY | -252.14 Million NOK | 29.89% |
| 2019 Q3 | -289.44 Million NOK | 10.7% |
| 2019 Q4 | -252.14 Million NOK | 12.89% |
| 2018 Q3 | -398.16 Million NOK | 9.77% |
| 2018 Q1 | -329.22 Million NOK | 10.93% |
| 2018 FY | -359.61 Million NOK | -2.96% |
| 2018 Q4 | -359.61 Million NOK | 9.68% |
| 2018 Q2 | -441.26 Million NOK | -34.03% |
| 2017 Q4 | -369.63 Million NOK | 7.4% |
| 2017 Q3 | -399.15 Million NOK | 9.35% |
| 2017 Q2 | -440.3 Million NOK | 0.0% |
| 2017 FY | -349.29 Million NOK | -143.95% |
| 2016 Q4 | -161.21 Million NOK | 0.0% |
| 2016 FY | -143.18 Million NOK | -98.11% |
| 2015 FY | -72.27 Million NOK | 42.8% |
| 2014 FY | -126.35 Million NOK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Arctic Bioscience AS | -77.55 Million NOK | -100.573% |
| Aqua Bio Technology ASA | -5.82 Million NOK | -2568.675% |
| ArcticZymes Technologies ASA | -237.27 Million NOK | 34.442% |
| Hofseth BioCare ASA | 112.89 Million NOK | 237.779% |
| PCI Biotech Holding ASA | -40.86 Million NOK | -280.655% |
| Thor Medical ASA | -41.28 Million NOK | -276.783% |
| Ultimovacs ASA | -262.84 Million NOK | 40.82% |